Info

Running Through Walls

Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969.
RSS Feed
Running Through Walls
2024
January


2023
December
November
October
September
June
May
March
January


2022
December
November
October
September
August
May
March
February
January


2021
December
October
August
June
May
April
March
February
January


2020
December
November
October
September
August
June
February
January


2019
December
November
August
May
April
January


2018
October
September
June
May
April
March
February
January


2017
December
November
October
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May


All Episodes
Archives
Now displaying: August, 2020
Aug 19, 2020

Following up on their discussion of COVID-19 vaccines and therapeutics, Venrock partner Bryan Roberts speaks with Mathai Mammen, Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, about Mammen’s career path and what differences he’s found working on drug development in both small companies and large companies. Managing 14,000 people has its challenges, but the scale is incredible: J&J’s products touch more than 1 billion people worldwide. They also discuss trends in gene editing and CRISPR thanks to machine learning and AI.

Aug 6, 2020

Venrock partner Bryan Roberts chats with Mathai Mammen about COVID-19 vaccine development and therapeutics in this special episode of Running Through Walls. Mammen serves as the Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, where he is heading up the firm’s COVID-19 vaccine development. They discuss J&J’s unique approach to the vaccine and which therapeutics are promising in the fight against the virus. Mammen shares how the U.S. can be better prepared for the next pandemic, and highlights how his company approaches vaccine production and distribution on a global scale.

1